Progression-free survival

What it is

Progression-free survival (PFS) is the time from random assignment in a clinical trial until cancer progression or death from any cause, a definition used by the U.S. National Cancer Institute. In cancer research, PFS is a trial endpoint, not a treatment itself. It is mainly used to compare how long patients in different study groups remain alive without the cancer getting worse.

PFS matters because it can often be measured earlier than overall survival (OS), which is the time until death from any cause. That can make trials faster and smaller, especially in advanced cancers where researchers want an earlier signal that a treatment is active. For patients and families, a reported result such as a longer median PFS means that, on average, the cancer took longer to show growth or spread in the treatment group being studied.

A simple way to think about PFS is:

Term	What counts as the event?
PFS	Tumour progression or death
OS	Death from any cause
Response rate	Tumour shrinkage meeting preset criteria

PFS is common in oncology drug trials, including studies of chemotherapy, targeted therapy, immunotherapy, and maintenance treatment. In India, patients may see PFS reported in trial summaries, hospital discussions, or regulatory and guideline documents when a new cancer medicine is being evaluated.

How it works

PFS is calculated using follow-up data collected after patients enter a trial. Participants usually have scheduled scans, clinical examinations, and sometimes biomarker tests. If imaging or clinical criteria show that the disease has progressed, that date is used as the event date. If a patient dies before documented progression, death also counts as a PFS event.

Most solid-tumour trials use standard rules such as RECIST to define progression on scans. In blood cancers, different disease-specific criteria may be used. Because progression is not always obvious on a single day, the exact way a trial defines and confirms progression matters.

Key features that affect PFS include:

1. Assessment schedule: Scans every 6 or 8 weeks may detect progression earlier than scans every 12 weeks.
2. Who reviews the scans: Local investigators and independent central reviewers may not always agree.
3. Definition of progression: Different cancers and trials may use different criteria.
4. Censoring: If a patient has not progressed by the last follow-up, their data are included up to that point rather than counted as an event.

Trial reports often present PFS in two ways:

• Median PFS: the time point at which 50% of patients have had progression or died.
• Hazard ratio (HR): a statistical comparison of the risk of progression or death between groups over time.

A longer median PFS or an HR below 1 can suggest benefit, but the size and clinical importance of that benefit still need careful interpretation.

Evidence and uses

PFS is widely used as a primary endpoint in oncology because it can show treatment activity earlier than OS and is not directly affected by later lines of therapy in the same way OS is. This is especially relevant in modern cancer care, where patients may receive multiple treatments after the study drug.

PFS can be useful when a treatment delays tumour growth, reduces symptoms related to progression, or postpones the need for more toxic therapy. In some settings, this is meaningful even if an OS benefit is hard to prove quickly. For example, crossover between trial arms or access to effective later treatments can blur OS differences.

At the same time, PFS is not always a reliable substitute for living longer. A 2020 analysis of metastatic solid tumour randomised trials found that PFS was a suboptimal predictor of overall survival at the trial level. Earlier methodological work has also pointed out that PFS can be affected by assessment timing, measurement bias, and differences in how progression is defined.

This means a PFS gain should be read alongside other outcomes, such as:

Outcome	Why it matters with PFS
Overall survival	Shows whether patients lived longer
Quality of life	Shows whether extra time without progression felt better or worse
Toxicity	Shows the cost of treatment benefit
Symptom control	Shows whether patients functioned better

For patients, the most important question is often not only "Did PFS improve?" but also "By how much, and at what cost?" A drug that improves median PFS by a few weeks with substantial side effects may be viewed differently from one that improves PFS by several months with manageable toxicity.

Diagnosis / how it's measured

PFS is not measured by a single blood test. It is estimated from trial follow-up using predefined rules. Researchers record the date of randomisation, then track each patient until one of the following happens:

• documented disease progression
• death from any cause
• last adequate assessment without progression

Progression is usually determined by imaging such as CT, MRI, or PET-CT, together with clinical findings. In some cancers, rising tumour markers alone may not be enough unless the protocol specifically allows that. Because scans happen at intervals, the exact date of progression is an approximation based on when it is detected.

When reading a paper, look for these details:

1. How progression was defined
2. How often scans were done
3. Whether review was blinded or independent
4. Median PFS in each arm
5. Hazard ratio and confidence interval

These details help show whether the PFS result is likely to be trustworthy and clinically meaningful.

When to see a clinician

If you are a patient or caregiver reading about PFS, ask your oncologist to explain what the number means for your specific cancer, stage, and treatment options. A trial result does not automatically predict what will happen for one individual.

It is reasonable to ask:

• Did the treatment also improve overall survival?
• How much was the PFS benefit in months?
• What side effects occurred?
• Did quality of life improve, stay the same, or worsen?
• Is this treatment available and appropriate in my setting in India?

These questions are especially important when comparing expensive therapies, maintenance treatment, or options that may delay progression without clearly helping patients live longer or feel better.

Limitations and open questions

PFS is useful, but it has limits. It depends on how often and how carefully doctors look for progression. If one trial scans more frequently than another, PFS results may not be directly comparable. Open-label trials can also introduce bias if investigators know which treatment a patient received.

Another limitation is that PFS does not by itself tell you whether a patient lived longer, felt better, or functioned better. A statistically significant PFS benefit may still be small in absolute terms. In some cancers and treatment settings, PFS correlates reasonably well with OS, but in others it does not.

Evidence also remains mixed on how well PFS reflects patient-centred outcomes such as symptom relief and psychological well-being. For that reason, many experts recommend interpreting PFS together with OS, adverse effects, and quality-of-life data rather than treating it as a complete measure of benefit.

For patients researching cancer care, the safest approach is to view PFS as one important piece of evidence, not the whole story.